2025-11-04

Q3 2025 Results

2025-08-05

Q2 2025 Results

2025-05-06

Q1 2025 Results

2024-11-05

Q3 2024 Results

Financial data not available in provided XBRL extract

2024-08-02

Q2 2024 Results

2024-05-07

Q1 2024 Results

2023-11-07

Q3 2023 Results

Financial figures not available in provided excerpt

2025-02-13

FY24 2024 Results

Data insufficient - revenue and EPS figures not extractable from provided XBRL tags

📌 Data insufficient - specific operational milestones not extractable from provided XBRL metadata

2024-02-15

FY 2023 Results

2025-11-03

Q3 2025 Earnings

Financial results for three and nine months ended September 30, 2025

2025-08-04

Q2 Earnings + CSO Retirement

David Altshuler CSO retiring Aug 2026

2025-05-19

Share Repurchase Program

$4B new buyback authorized, $4.775B total capacity

2025-05-14

Annual Shareholder Meeting

11 directors elected, Ernst & Young ratified as auditor

2025-05-05

Q1 2025 Earnings

Q1 2025 financial results reported May 5, 2025

2025-03-28

VX-264 Program Discontinued

$400M impairment charge for Q1 2025

2025-02-10

Q4 Earnings + COO Change

Stuart Arbuckle COO retires July 1, CFO Wagner adds COO role

2024-12-20

FDA Approves ALYFTREK

ALYFTREK approved for cystic fibrosis, priced at $370,269 annually

2024-11-04

Q3 Earnings

Q3 2024 financial results reported

2024-08-16

Headquarters Lease Extension

1.1M sq ft lease extended to June 2044

2024-08-01

Q2 Earnings

Q2 2024 financial results reported

2024-06-27

Alpine Acquisition Accounting Impact

$4.4B AIPR&D expense from $5B Alpine acquisition

2024-05-20

Acquired Alpine Immune Sciences

$5.0B equity value deal completed

2024-05-15

Annual Shareholder Meeting

11 directors elected, auditor ratified, exec comp approved

2024-05-06

Q1 2024 Earnings

Q1 2024 financial results reported

2024-04-11

Acquired Alpine Immune Sciences

$65/share cash tender offer

2024-02-05

Q4 2023 Earnings

Q4 and full year 2023 financial results reported

2023-12-08

FDA Approves CASGEVY

Gene therapy for sickle cell disease, $2.2M wholesale price

2023-12-05

Nancy Thornberry Appointed to Board

Board expanded from 10 to 11 members, $400K RSU grant